atazanavir sulfate has been researched along with Kidney Diseases in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Nabulsi, M; D'Agati, VD; Markowitz, GS; Reddy, A; Salamera, J; Santoriello, D | 1 |
| Firląg-Burkacka, E; Grycner, E; Horban, A; Kowalska, JD; Matłosz, B; Pietraszkiewicz, E | 1 |
| Arai, M; Satoh, M; Tanaka, H; Tomoda, Y; Wada, T; Yago, K | 1 |
| Antela, A; Jiménez-Expósito, MJ; Knechten, H; Kuhlmann, B; Rocha-Pereira, N; Santos, J; Teófilo, E | 1 |
| Post, FA | 1 |
| Chadwick, D; Hamzah, L; Jones, R; Jose, S; Nelson, M; Phillips, A; Post, FA; Sabin, CA; Trevelion, R; Williams, DI | 1 |
| López-Cortés, LF | 1 |
| Antela López, A | 1 |
| Cooper, RD; Tonelli, M | 1 |
| Allavena, C; Dejesus, E; Fernandez Garcia, E; Fisher, M; Hardy, WD; Jackson, AG; Jayaweera, DT; Katlama, C; Mauss, S; Moyle, GJ; Raffi, F; Reiss, P; Slama, L; van Eeden, A; Vrouenraets, SM; Wit, FW | 1 |
| Borderi, M; Calza, L; Colangeli, V; Di Bari, MA; Magistrelli, E; Manfredi, R; Salvadori, C; Trapani, F; Viale, P | 1 |
| Aboulker, JP; Chazallon, C; Gérard, L; Girard, PM; Piketty, C; Taburet, AM | 1 |
4 review(s) available for atazanavir sulfate and Kidney Diseases
| Article | Year |
|---|---|
Managing chronic kidney disease in the older adults living with HIV.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Chronic Disease; Darunavir; Drug Substitution; HIV Infections; Humans; Kidney; Kidney Diseases; Lopinavir; Middle Aged; Tenofovir | 2017 |
[Pharmacology, pharmacokinetic features and interactions of atazanavir].
Topics: Anti-HIV Agents; Atazanavir Sulfate; Biological Availability; Biotransformation; Blood Proteins; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Fetal Blood; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Infant, Newborn; Kidney Diseases; Liver Diseases; Maternal-Fetal Exchange; Metabolic Clearance Rate; Molecular Structure; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Pyridines | 2008 |
[Utility of atazanavir in special populations].
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cardiovascular Diseases; Child; Child, Preschool; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Emigrants and Immigrants; Female; Heroin Dependence; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Hyperbilirubinemia, Neonatal; Infant; Infant, Newborn; Insulin Resistance; Kidney Diseases; Liver Diseases; Male; Methadone; Multicenter Studies as Topic; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Pyridines; Young Adult | 2008 |
Renal disease associated with antiretroviral therapy in the treatment of HIV.
Topics: Adenine; Anti-Retroviral Agents; Atazanavir Sulfate; HIV Infections; Humans; Indinavir; Kidney Diseases; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2011 |
3 trial(s) available for atazanavir sulfate and Kidney Diseases
| Article | Year |
|---|---|
Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study.
Topics: Adolescent; Adult; Atazanavir Sulfate; Cohort Studies; Drug Administration Schedule; Europe; Female; HIV Infections; HIV-1; Humans; Kidney Diseases; Male; Middle Aged; Ritonavir; Treatment Outcome; Young Adult | 2016 |
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.
Topics: Adenine; Adult; Atazanavir Sulfate; Deoxycytidine; Drug Administration Schedule; Dyslipidemias; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Male; Oligopeptides; Organophosphonates; Pyridines; Saquinavir; Tenofovir; Treatment Outcome | 2011 |
Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Creatinine; Female; France; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Male; Middle Aged; Models, Biological; Oligopeptides; Organophosphonates; Prognosis; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2007 |
5 other study(ies) available for atazanavir sulfate and Kidney Diseases
| Article | Year |
|---|---|
Atazanavir-Associated Crystalline Nephropathy.
Topics: Atazanavir Sulfate; Crystallization; HIV Protease Inhibitors; Humans; Kidney Diseases; Male; Middle Aged | 2017 |
Risk factors for kidney disease among HIV-1 positive persons in the methadone program.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; Humans; Indinavir; Kidney Diseases; Male; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Poland; Risk Factors; Sex Factors; Tenofovir; Time Factors | 2019 |
Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Combinations; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir | 2013 |
Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.
Topics: Adult; Atazanavir Sulfate; Cohort Studies; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Male; Middle Aged; Treatment Outcome; United Kingdom | 2017 |
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; Glycosuria; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Proteinuria; Pyridines; Retrospective Studies; Ritonavir; Tenofovir | 2013 |